Title:
EPCAM ANTIBODY AND CAR-T CELLS
Document Type and Number:
WIPO Patent Application WO/2021/211510
Kind Code:
A3
Abstract:
The present invention provides EpCAM antibodies with different affinities. The present invention also provides chimeric antigen receptors (CARs) specific to EpCAM. CAR T cells comprising human EpCAM scFv having a low and sufficient affinity to EpCAM can avoid targeting healthy tissues with low EpCAM expression while exhibiting long-term efficacy against tumor tissues with high EpCAM expression. The present invention also relates to an adoptive cell therapy method for treating cancer by administering the CAR-T cells comprising human EpCAM scFv to a subject suffering from cancer, whereby the CAR T cells bind to the cancer cells overexpressing EpCAM and kill the cancer cells.
More Like This:
Inventors:
YANG HUAN (US)
JIN MOONSOO (US)
PUC JANUSZ (US)
JIN MOONSOO (US)
PUC JANUSZ (US)
Application Number:
PCT/US2021/026980
Publication Date:
November 25, 2021
Filing Date:
April 13, 2021
Export Citation:
Assignee:
AFFYIMMUNE THERAPEUTICS INC (US)
International Classes:
C07K16/46; A61K35/13; A61K35/17
Foreign References:
| US20070128183A1 | 2007-06-07 | |||
| US20070054362A1 | 2007-03-08 |
Other References:
ANG ET AL.: "Intraperitoneal immunotherapy with T cells stably and transiently expressing anti- EpCAM CAR in xenograft models of peritoneal carcinomatosis", ONCOTARGET, vol. 8, no. 8, 21 February 2017 (2017-02-21), pages 13545 - 13559, XP055727359, DOI: 10.18632/oncotarget.14592
Attorney, Agent or Firm:
KUNG, Viola T. et al. (US)
Download PDF:
Previous Patent: SWAB AND METHOD OF MANUFACTURING A SWAB
Next Patent: CHEMICAL RECYCLING OF RECLAIMER FLAKE REJECT
Next Patent: CHEMICAL RECYCLING OF RECLAIMER FLAKE REJECT